Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions

T-cell lymphomas are a relatively rare group of malignancies with a diverse range of pathologic features and clinical behaviors. Recent molecular studies have revealed a wide array of different mechanisms that drive the development of these malignancies and may be associated with resistance to thera...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maliha Khan, Felipe Samaniego, Fredrick B. Hagemeister, Swaminathan P. Iyer
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	PTCL non-Hodgkin’s lymphoma novel therapies targeted therapies recent advances current treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0350a11afc3c432e9a8a4dcf33f96c59
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0350a11afc3c432e9a8a4dcf33f96c59
record_format	dspace
spelling	oai:doaj.org-article:0350a11afc3c432e9a8a4dcf33f96c592021-11-25T17:01:48ZEmerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions10.3390/cancers132256272072-6694https://doaj.org/article/0350a11afc3c432e9a8a4dcf33f96c592021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5627https://doaj.org/toc/2072-6694T-cell lymphomas are a relatively rare group of malignancies with a diverse range of pathologic features and clinical behaviors. Recent molecular studies have revealed a wide array of different mechanisms that drive the development of these malignancies and may be associated with resistance to therapies. Although widely accepted chemotherapeutic agents and combinations, including stem cell transplantation, obtain responses as initial therapy for these diseases, most patients will develop a relapse, and the median survival is only 5 years. Most patients with relapsed disease succumb within 2 to 3 years. Since 2006, the USFDA has approved five medications for treatment of these diseases, and only anti-CD30-therapy has made a change in these statistics. Clearly, newer agents are needed for treatment of these disorders, and investigators have proposed studies that evaluate agents that target these malignancies and the microenvironment depending upon the molecular mechanisms thought to underlie their pathogenesis. In this review, we discuss the currently known molecular mechanisms driving the development and persistence of these cancers and discuss novel targets for therapy of these diseases and agents that may improve outcomes for these patients.Maliha KhanFelipe SamaniegoFredrick B. HagemeisterSwaminathan P. IyerMDPI AGarticlePTCLnon-Hodgkin’s lymphomanovel therapiestargeted therapiesrecent advancescurrent treatmentNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5627, p 5627 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	PTCL non-Hodgkin’s lymphoma novel therapies targeted therapies recent advances current treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	PTCL non-Hodgkin’s lymphoma novel therapies targeted therapies recent advances current treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Maliha Khan Felipe Samaniego Fredrick B. Hagemeister Swaminathan P. Iyer Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions
description	T-cell lymphomas are a relatively rare group of malignancies with a diverse range of pathologic features and clinical behaviors. Recent molecular studies have revealed a wide array of different mechanisms that drive the development of these malignancies and may be associated with resistance to therapies. Although widely accepted chemotherapeutic agents and combinations, including stem cell transplantation, obtain responses as initial therapy for these diseases, most patients will develop a relapse, and the median survival is only 5 years. Most patients with relapsed disease succumb within 2 to 3 years. Since 2006, the USFDA has approved five medications for treatment of these diseases, and only anti-CD30-therapy has made a change in these statistics. Clearly, newer agents are needed for treatment of these disorders, and investigators have proposed studies that evaluate agents that target these malignancies and the microenvironment depending upon the molecular mechanisms thought to underlie their pathogenesis. In this review, we discuss the currently known molecular mechanisms driving the development and persistence of these cancers and discuss novel targets for therapy of these diseases and agents that may improve outcomes for these patients.
format	article
author	Maliha Khan Felipe Samaniego Fredrick B. Hagemeister Swaminathan P. Iyer
author_facet	Maliha Khan Felipe Samaniego Fredrick B. Hagemeister Swaminathan P. Iyer
author_sort	Maliha Khan
title	Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions
title_short	Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions
title_full	Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions
title_fullStr	Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions
title_full_unstemmed	Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions
title_sort	emerging therapeutic landscape of peripheral t-cell lymphomas based on advances in biology: current status and future directions
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/0350a11afc3c432e9a8a4dcf33f96c59
work_keys_str_mv	AT malihakhan emergingtherapeuticlandscapeofperipheraltcelllymphomasbasedonadvancesinbiologycurrentstatusandfuturedirections AT felipesamaniego emergingtherapeuticlandscapeofperipheraltcelllymphomasbasedonadvancesinbiologycurrentstatusandfuturedirections AT fredrickbhagemeister emergingtherapeuticlandscapeofperipheraltcelllymphomasbasedonadvancesinbiologycurrentstatusandfuturedirections AT swaminathanpiyer emergingtherapeuticlandscapeofperipheraltcelllymphomasbasedonadvancesinbiologycurrentstatusandfuturedirections
_version_	1718412753786372096

Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions

Ejemplares similares